Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
David Kwiatkowski is a Professor of Medicine at Harvard Medical School, and Senior Physician at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. He earned a BSc from Caltech and a PhD from MIT, both in Mathematics. He received his MD degree from Columbia University, and received the Janeway Prize at graduation for the highest achievement and abilities in the graduating medical class. He pursued Internal Medicine and then Hematology-Oncology training at the Massachusetts General Hospital, and remained at MGH until 1991 when he moved to BWH/DFCI. Dr. Kwiatkowski has specialized in thoracic oncology, and has broad interests in all types of thoracic malignancies, including lung cancer, thymic cancer, and mesothelioma. He is a self-trained human and cancer geneticist, and has been the leader of the Dana-Farber/Harvard Cancer Center Cancer Genetics program since 2007. He is an Associate Member of the Broad Institute, and an active participant in The Cancer Genome Atlas (TCGA), working on multiple cancer types and programs. His current patient research interests are: personalized/targeted treatment of cancers according to their mutations, targeting the mTOR pathway in cancer, and mesothelioma therapeutic development and treatment. He has a much deeper familiarity with mesothelioma than the average thoracic oncologist, and sees many patients on referral from around the country.
mTOR signaling in cancer: therapeutic target
I have broad interests in human cancer genetics, and have been Program Leader for the DFHCC Cancer Genetics program for the past 8 years. I am an Associate Member of the Broad Institute, and have been active in multiple NCI TCGA (The Cancer Genome Atlas) projects, including adenocarcinoma and squamous cell carcinoma of the lung, bladder cancer, kidney chromophobe cancer, mesothelioma, and pathway analyses. It has become apparent that a variety of cancers (partially due to our analyses) have mutations in TSC1 or TSC2 at rates of 1 – 10%. Moreover, in some cases TSC1/TSC2-mutant cancers are highly sensitive to treatment with rapalogs, with durable CRs lasting several years. We are studying these patients to elucidate the genetic and other determinants of response to rapalogs, and investigating synergistic treatment approaches. I am the PI of a Novartis-sponsored Investigator-initiated trial to treat all cancers with mutations in either TSC1 or TSC2 with everolimus. A variety of correlative genetic studies will be done as part of that trial. We generated a mouse model of mesothelioma due to mutation and loss of Tsc1, and demonstrated that these tumors were highly sensitive to treatment with rapalogs. We also demonstrated some degree of mTOR activation in both mesothelioma cell lines and resected patient mesotheliomas. This has led to enhanced interest in therapeutic strategies for mesothelioma, which although a rare malignancy overall, is commonly seen at BWH/DFCI. I am engaged in several efforts to develop novel therapeutic approaches and clinical trials for mesothelioma.
Brigham and Women's Hospital75 Francis StreetOne Blackfan Circle 6-216Boston, MA 02215Get Directions